{"id":881686,"date":"2025-09-03T16:20:53","date_gmt":"2025-09-03T20:20:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/"},"modified":"2025-09-03T16:20:53","modified_gmt":"2025-09-03T20:20:53","slug":"aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/","title":{"rendered":"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Sept.  03, 2025  (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 \u2013 12, 2025 in Berlin, Germany.<\/p>\n<p>The company and its collaborators\u2019 commitment to advancing next-generation therapies for liver and viral diseases is reflected in these presentations, with topics spanning novel approaches, molecular strategies, insights into the mechanisms of action of ALG-000184, as well as a new strategy to potentially cure hepatitis delta virus (HDV) infection utilizing a proprietary antisense oligonucleotide (ASO) approach.<\/p>\n<p>\u201cWe are pleased to present six preclinical presentations at the International HBV Meeting, that showcase our continued innovation in liver and viral diseases. With the Phase 2 B-Supreme study progressing nicely, we are pleased to present, for the first time, the direct effects of ALG-000184 in reducing HBV cccDNA in a preclinical setting. These data help corroborate the clinical observations of HBV antigen reductions seen in patients with chronic HBV infection treated with ALG-000184 monotherapy to date and are a direct indication that ALG-000184 can invoke the secondary mechanism of CAM-Es,\u201d stated Lawrence Blatt, PhD, MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. \u201cWhile we remain committed to the continued development of our best\/first-in-class CAM-E ALG-000184 for chronic HBV infection, we are pleased to broaden our pipeline with the presentation of our discovery stage ASO program for the treatment of HDV. HDV coinfection with HBV leads to more rapid disease progression and our ASO uniquely targets the destruction of the viral genome, making this mechanism uniquely suited towards a potential HDV cure. Ongoing work will be aimed at selection of the HDV-targeted ASO clinical development candidate.\u201d<\/p>\n<p>Details on the presentations are as follows:<\/p>\n<p>\n        <strong>Paper #:<\/strong> 52<br \/><strong>Type:<\/strong> Oral Presentation<br \/><strong>Title: <\/strong><em>The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments<\/em><br \/><strong>Presenter:<\/strong> Yannick Debing, PhD<br \/><strong>Date\/Time:<\/strong> September 11, 2025 at 10:30am \u2013 12:00pm CET<br \/><strong>Session: <\/strong>Session X: Therapy II<\/p>\n<p>\n        <strong>Paper #: <\/strong>53<br \/><strong>Type:<\/strong> Oral Presentation<br \/><strong><em>Title: <\/em><\/strong><em>Antisense\u00a0oligonucleotide-based\u00a0strategy to target\u00a0hepatitis delta virus\u00a0infections<\/em><br \/><strong>Presenter:<\/strong> Julie Lucifora, PhD, CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Universit\u00e9 Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon<br \/><strong>Date\/Time:<\/strong> September 11, 2025 at 10:30am \u2013 12:00pm CET<br \/><strong>Session:<\/strong> Session X: Therapy II<\/p>\n<p>\n        <strong>Paper #: <\/strong>2<br \/><strong>Type:<\/strong> Oral Presentation<br \/><strong><em>Title: <\/em><\/strong><em>A Syrian hamster model of persistent HDV infection<\/em><br \/><strong>Presenter:<\/strong> Elias Broeckhoven, KU Leuven, Department of Microbiology, Immunology &amp; Transplantation, Rega Institute; Virology, Antiviral Drug and Vaccine Research Group; Laboratory of Molecular Vaccinology &amp; Vaccine Discovery (MVVD)<br \/><strong>Date\/Time:<\/strong> September 8, 2025 at 5:00pm \u2013 6:30pm CET<br \/><strong>Session:<\/strong> Molecular Virology I<\/p>\n<p>\n        <strong>Paper #:<\/strong> 283<br \/><strong>Type:<\/strong> Poster Presentation<br \/><strong>Title: <\/strong><em>Differential impact of CAM-E and CAM-A on hepatitis B core protein phosphorylation states in vitro<\/em><br \/><strong>Presenter:<\/strong> Hannah Vanrusselt<br \/><strong>Date\/Time:<\/strong> September 10, 2025 at 11:00am \u2013 12:00pm CET<br \/><strong>Session:<\/strong> Poster Session II<\/p>\n<p>\n        <strong>Paper #:<\/strong> 285<br \/><strong>Type:<\/strong> Poster Presentation<br \/><strong>Title: <\/strong><em>Capsid assembly modulators bind and directly target HBeAg<\/em><br \/><strong>Presenter:<\/strong> Jordi Verheyen<br \/><strong>Date\/Time:<\/strong> September 10, 2025 at 11:00am \u2013 12:00pm CET<br \/><strong>Session:<\/strong> Poster Session II<\/p>\n<p>\n        <strong>Paper #: <\/strong>127<br \/><strong>Type:<\/strong> Poster Presentation<br \/><strong><em>Title: <\/em><\/strong><em>PML nuclear bodies store aggregated HBc and reduce CAM-induced apoptosis in HBc-expressing cells<\/em><br \/><strong>Presenter:<\/strong> Vaclav Janovec, PhD, University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences<br \/><strong>Date\/Time:<\/strong> September 8, 2025 at 5:00pm \u2013 6:30pm CET<br \/><strong>Session:<\/strong> Molecular Virology<\/p>\n<p>The presentations can be found on the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MWu6GtW7XZEvjQTNos2xkUS3x4LMj5NRPtafiXYLXmya_d19voI2F7x1TPSCwd9aMvtQLiBwW4tMfIbU_9g0XFhnzUVoAgYDdHLjvsDhb33eNpY-GgKGKWPa-6e2NxibQ2K6yM6a2zdaUnmQfsiq2Q==\" rel=\"nofollow\" target=\"_blank\">Posters<u> &amp; Presentations<\/u><\/a>\u00a0section of the Aligos website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UfXnmTmZhG1Mu_IgST9v188V1K0bOoztyV8JRjL0GEKu4e6_h2YPi1D8ZyalcT1nWSe3fwFE3oGk5BCtuZO29j8DiuLTOEUsjDlh7lDjE_LEm7SJVQVB3tVXsQi1cb2MsMc-HphHle4NJH314aq0fDWcupgVNeAsy05tx8mI2a7rb0sU9TU2najhZ5yNu9r4IMSakgr1Hjt2xipo7tiEKq4k62HJPOELmgESwYFq1h216qscwt3PrwmJhaY98CixCewIeqGycDesXvieaEhNvWzWLALn-JdADci1qH4xySpnLFR6eSJQhTn9-3O5GyAjm23gILd1jc4SKOmHbNaNF7Z21j0XJvy_mQ8j9e2qZC3UbFMh6iqJIkoRbVFM0G4dCpEgsk0V78Y2eyyyV1amZ1OWvHUq1iMc88Z9Nr4rkwGC2L0Z3qdiM5CSuf35O44P\" rel=\"nofollow\" target=\"_blank\"><u>www.aligos.com<\/u><\/a>) after the live event.<\/p>\n<p>\n        <strong>About Aligos<\/strong>\n      <\/p>\n<p>Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&amp;D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UfXnmTmZhG1Mu_IgST9v1yztQcsjw_a2hNr0lmgx_iwrs2T7IZmm64OXzGF16W9jWXPX4d7EvDmjhwBW0fLT4Q==\" rel=\"nofollow\" target=\"_blank\">www.aligos.com<\/a> or follow us on LinkedIn or X.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered \u201cforward-looking statements,\u201d including without limitation, statements regarding Aligos\u2019 financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos\u2019 clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos\u2019 capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos\u2019 Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.\u00a0\u00a0 <\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Aligos Therapeutics, Inc.<br \/>Jordyn Tarazi<br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/>+1 (650) 910-0427<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M0zl3GqYI06VXklFvDY9cMX3ZHnot8GiAwsg7ohrBhFzGEYFmB61wQBGlVZvdLkladnLoKlx0gLM7voYkKE0lkghZVHOTlZesz6jAufIdmg=\" rel=\"nofollow\" target=\"_blank\">jtarazi@aligos.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Inizio Evoke<br \/>Jake Robison<br \/>Vice President<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1KuOAhWSJrMBFjp5yHYyWYEvYVn4aPVwhidG8fZFztg1KcPJi_-_eNRRLYch3s-6f55wbDICA2cDncknr18QSkFD6dE1yqAZwtchA64u-sKr3BlphhIeBLyhJn_Hvcnm\" rel=\"nofollow\" target=\"_blank\">Jake.Robison@inizioevoke.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc1NiM3MTI4MTE5IzIyMDM5MTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjBkZWY5NDYtZmJlZi00NmQyLWJkMTEtZGM4ODQ5NGJiYjY3LTEyMTU0NjktMjAyNS0wOS0wMy1lbg==\/tiny\/Aligos-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 \u2013 12, 2025 in Berlin, Germany. The company and its collaborators\u2019 commitment to advancing next-generation therapies for liver and viral diseases is reflected in these presentations, with topics spanning novel approaches, molecular strategies, insights into the mechanisms of action of ALG-000184, as well as a new strategy to potentially cure hepatitis delta virus (HDV) infection utilizing a proprietary antisense oligonucleotide (ASO) approach. \u201cWe are pleased to present six preclinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-881686","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 \u2013 12, 2025 in Berlin, Germany. The company and its collaborators\u2019 commitment to advancing next-generation therapies for liver and viral diseases is reflected in these presentations, with topics spanning novel approaches, molecular strategies, insights into the mechanisms of action of ALG-000184, as well as a new strategy to potentially cure hepatitis delta virus (HDV) infection utilizing a proprietary antisense oligonucleotide (ASO) approach. \u201cWe are pleased to present six preclinical &hellip; Continue reading &quot;Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T20:20:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc1NiM3MTI4MTE5IzIyMDM5MTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting\",\"datePublished\":\"2025-09-03T20:20:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/\"},\"wordCount\":958,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjc1NiM3MTI4MTE5IzIyMDM5MTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/\",\"name\":\"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjc1NiM3MTI4MTE5IzIyMDM5MTY=\",\"datePublished\":\"2025-09-03T20:20:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjc1NiM3MTI4MTE5IzIyMDM5MTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjc1NiM3MTI4MTE5IzIyMDM5MTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 \u2013 12, 2025 in Berlin, Germany. The company and its collaborators\u2019 commitment to advancing next-generation therapies for liver and viral diseases is reflected in these presentations, with topics spanning novel approaches, molecular strategies, insights into the mechanisms of action of ALG-000184, as well as a new strategy to potentially cure hepatitis delta virus (HDV) infection utilizing a proprietary antisense oligonucleotide (ASO) approach. \u201cWe are pleased to present six preclinical &hellip; Continue reading \"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-03T20:20:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc1NiM3MTI4MTE5IzIyMDM5MTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting","datePublished":"2025-09-03T20:20:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/"},"wordCount":958,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc1NiM3MTI4MTE5IzIyMDM5MTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/","name":"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc1NiM3MTI4MTE5IzIyMDM5MTY=","datePublished":"2025-09-03T20:20:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc1NiM3MTI4MTE5IzIyMDM5MTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc1NiM3MTI4MTE5IzIyMDM5MTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-announces-six-preclinical-presentations-at-the-2025-international-hbv-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=881686"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881686\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=881686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=881686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=881686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}